The life expectancy of leukemia patients may be nearly doubled by the use of Amgen’s new immunotherapy drug, according the results of a clinical trial published March 1 in the New England Journal of Medicine.
Alere Inc. has announced that its respiratory syncytial virus test has been granted a Clinical Laboratory Improvement Amendments waiver by the Food and Drug Administration, paving the way for the test to be available to doctors, walk-in clinics and emergency rooms.
Although omega-3 fish oil supplements may reduce the risk of death following a heart attack, there is a lack of scientific research to support using these supplements to prevent heart disease in people who have not a heart attack, according to an advisory from the American Heart Association (AHA).
Patients who visit an emergency room fearing they are suffering from a serious condition should be covered by their insurance regardless of the final diagnosis, according to the president of the American College of Emergency Physicians (ACEP).
The American Heart Association (AHA) has released its Precision Medicine Platform, a cloud-based resource with data geared to help doctors, computational biologists, researchers and computer engineers battle cardiovascular diseases and stroke.
Aeolus Pharmaceuticals Inc. recently reported that its AEOL 20415 protected the lungs in a mouse model of cystic fibrosis, increasing further speculation that the drug could be used as both a treatment for cystic fibrosis, as well as antibiotic-resistant bacteria.
Merck and Pfizer Inc. said the U.S. Food and Drug Administration (FDA) has agreed to review three New Drug Applications for medications containing ertugliflozin that treat glycemic control in adults with type 2 diabetes.